Rafferty Asset Management, LLC - BIOXCEL THERAPEUTICS INC ownership

BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 98 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.0%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of BIOXCEL THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$1,316,242
-52.7%
197,634
+32.5%
0.01%
-63.2%
Q1 2023$2,782,430
+43.2%
149,112
+60.5%
0.02%
+58.3%
Q1 2022$1,943,000
-3.1%
92,928
-5.8%
0.01%
+9.1%
Q4 2021$2,005,000
+10.5%
98,638
+64.9%
0.01%
-8.3%
Q3 2021$1,815,000
-9.3%
59,803
-13.2%
0.01%
-7.7%
Q2 2021$2,002,000
-34.6%
68,900
-2.9%
0.01%
-38.1%
Q1 2021$3,061,000
+206.4%
70,924
+228.0%
0.02%
+110.0%
Q4 2020$999,000
-47.8%
21,624
-51.0%
0.01%
-56.5%
Q3 2020$1,914,000
+158.6%
44,152
+216.3%
0.02%
+130.0%
Q2 2020$740,00013,9600.01%
Other shareholders
BIOXCEL THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Logos Global Management LP 550,000$23,848,0003.05%
SPHERA FUNDS MANAGEMENT LTD. 269,300$11,677,0001.15%
Avidity Partners Management LP 538,000$23,328,0001.08%
Knoll Capital Management, LLC 20,000$867,0000.71%
Maven Securities LTD 200,000$8,610,0000.71%
Prosight Management, LP 29,800$1,292,0000.62%
Artemis Investment Management LLP 1,001,708$43,383,0000.54%
Ikarian Capital, LLC 150,000$6,504,0000.47%
AlphaCentric Advisors LLC 20,000$867,0000.42%
MOODY ALDRICH PARTNERS LLC 19,872$862,0000.18%
View complete list of BIOXCEL THERAPEUTICS INC shareholders